GSK, Pfizer combining efforts to boost role in AIDS market

04/16/2009 | Bloomberg

GlaxoSmithKline and Pfizer are forming a company to combine their HIV-drug businesses, hoping to gain a nearly 20% share of the $12.3 billion AIDS market that Gilead Sciences dominates. GSK will take control of 85% of the firm, which will own 11 medicines on the market and six experimental treatments.

View Full Article in:

Bloomberg

Published in Brief:

SmartBrief Job Listings for Health Care

Job Title Company Location
Chief Financial Officer
B. E. Smith
Miramar, FL
Claims Director
PacificSource
Springfield, OR
Consultant
Attest Health Care Advisors
Nationwide, SL_Nationwide
Biotechnology/Pharmaceutical Patent Attorney
Coats and Bennett PLLC
Cary, NC
Sr. Regulatory Specialist, Biotech Center of Expertise
BASF, The Chemical Co.
San Diego, CA